dogchasingcogChasingCars

XBI - On the verge of ANOTHER historic 300% run?

Viés de alta
AMEX:XBI   SPDR Series Trust SPDR S&P Biotech ETF
First 5 years were quite disappointing for XBI, as it was locked in a big "penalty box" from the spring of '06 to the spring of 2011... BUT is was slowly building a BIG ascending triangle, fraught with false breakouts (blue arrow), and FINALLY, a break-and-retest of the all time highs (green arrow). From this ATH (upper boundary of the box), to the blow-off top in July 2015, the NET gain was almost 300% over 4 years, on an UNLEVERAGED, DIVERSIFIED ETF!!!
How cool would it be if history repeated itself? XBI found itself again inside of a big nasty "penalty box" over the last 5/6 years, BUT it managed to form a BIG ascending triangle, fraught with false breakouts (blue arrows), and FINALLY, a break-and-retest of all time highs (green arrow). Will it quadruple over the next years just like last time? In 2011, rates had been cut aggressively and the world was coming out of a backbreaking recession... Sounds familiar? Just beware of externalities that may rock the boat!! In Agust 2011, the US debt downgrade and the European debt crisis plunged equities into a hole, but for biotech, it was only one last scary shakeout (red arrow) before a historic run!

Full disclosure: I own several biotech stocks totaling over 20% of total assets, and am actively seeking to increase my exposure to this sector. While I don't own XBI, I have reccomended it and similar funds to people unable or unwilling to buy individual stocks. Only buy the amount of stock that you can be sure to hold in the worst market conditions. The bigger the potential upside,
the bigger the risk of temporary drawdowns. And they come when you LEAST expect them. Just look at June-August 2011... Buy on pullbacks, NEVER chase prices.
Aviso legal

As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.